NCT05051930

A Clinical Trial of TQC3721 Suspension for Inhalation

Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Efficacy of TQC3721 Suspension for Inhalation

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 114 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

To evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3721 suspension for inhalation in single/multiple administration(s) in healthy subjects; to evaluate the safety,tolerability and efficacy TQC3721 suspension for inhalation in multiple administrations in patients with Chronic Obstructive Pulmonary Disease（COPD）and asthma.

Conditions

• Chronic Obstructive Pulmonary Disease

Interventions

Type	Name	Description
DRUG	TQC3721 suspension for inhalation	Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.
DRUG	TQC3721 suspension placebo for inhalation	Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .

Timeline

• Start date: 2021-10-18
• Primary completion: 2022-10-31
• Completion: 2022-12-31
• First posted: 2021-09-21
• Last updated: 2021-10-25

Locations

1 site across 1 country: China